Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jun 11;6(6):CD003506.
doi: 10.1002/14651858.CD003506.pub2.

Early versus deferred standard androgen suppression therapy for advanced hormone-sensitive prostate cancer

Frank Kunath  1 , Katrin Jensen, Mariona Pinart, Andreas Kahlmeyer, Stefanie Schmidt, Carrie L Price, Verena Lieb, Philipp Dahm
Affiliations

Early versus deferred standard androgen suppression therapy for advanced hormone-sensitive prostate cancer

Frank Kunath et al. Cochrane Database Syst Rev. .

Abstract

Background: Standard androgen suppression therapy (AST) using surgical or medical castration is considered a mainstay of advanced hormone-sensitive prostate cancer treatment. AST can be initiated early when disease is asymptomatic or deferred when patients suffer symptoms of disseminated prostate cancer.

Objectives: To assess the effects of early versus deferred standard AST for advanced hormone-sensitive prostate cancer.

Search methods: For this Cochrane Review update, we performed a comprehensive search of multiple databases (CENTRAL, MEDLINE, Embase, Web of Science; last searched November 2018) and two clinical trial registers, with no restrictions on the language of publication or publication status. We also searched bibliographies of included studies and conference proceedings (last searched January 2019).

Selection criteria: We included all randomised controlled trials (RCTs) with a direct comparison of early versus deferred standard AST. We excluded all other study designs. Participants included had advanced hormone-sensitive prostate cancer receiving surgical or medical castration.

Data collection and analysis: Two review authors independently classified studies and abstracted data. The primary outcomes were time to death of any cause and serious adverse events. Secondary outcomes were time to disease progression, time to death from prostate cancer, adverse events and quality of life. We performed statistical analyses using a random-effects model and assessed the certainty of evidence according to GRADE. We performed subgroup analyses for advanced but non-metastatic disease (T2-4/N+ M0), metastatic disease (M1), and prostate-specific antigen (PSA) relapse.

Main results: We identified seven new RCTs since publication of the original review in 2002. In total, we included 10 RCTs.Primary outcomesEarly AST probably reduces the risk of death from any cause over time (hazard ratio (HR) 0.82, 95% confidence interval (CI) 0.75 to 0.90; moderate-certainty evidence; 4767 participants). This corresponds to 57 fewer deaths (95% CI 80 fewer to 31 fewer) per 1000 participants at 5 years for the moderate risk group and 23 fewer deaths (95% CI 32 fewer to 13 fewer) per 1000 participants at 5 years in the low risk group. We downgraded for study limitations. Early versus deferred AST may have little or no effect on serious adverse events (risk ratio (RR) 1.05, 95% CI 0.95 to 1.16; low-certainty evidence; 10,575 participants) which corresponds to 6 more serious adverse events (6 fewer to 18 more) per 1000 participants. We downgraded the certainty of evidence for study limitations and selective reporting.Secondary outcomesEarly AST probably reduces the risk of death from prostate cancer over time (HR 0.69, 95% CI 0.57 to 0.84; moderate-certainty evidence). This corresponds to 62 fewer prostate cancer deaths per 1000 (95% CI 87 fewer to 31 fewer) at 5 years for the moderate risk group and 24 fewer death from prostate cancer (95% CI 34 fewer to 12 fewer) per 1000 men at 5 years in the low risk group. We downgraded the certainty of evidence for study limitations.Early AST may decrease the rate of skeletal events (RR 0.37, 95% CI 0.17 to 0.80; low-certainty evidence) corresponding to 23 fewer skeletal events per 1000 (95% CI 31 fewer to 7 fewer). We downgraded for study limitations and imprecision. It may also increase fatigue (RR 1.41, 95% CI 1.23 to 1.62; low-certainty evidence), corresponding to 31 more men with this complaint per 1000 (95% CI 18 more to 48 more). We downgraded for study limitations and imprecision. It may increase the risk of heart failure (RR 1.90, 95% CI 1.09 to 3.33; low-certainty evidence) corresponding to 27 more events per 1000 (95% CI 3 more to 69 more). We downgraded the certainty of evidence for study limitations and imprecision.Global quality of life is probably similar after two years as assessed with the EORTC QLQ-C30 (version 3.0) questionnaire (mean difference -1.56, 95% CI -4.50 to 1.38; moderate-certainty evidence) with higher scores reflecting better quality of life. We downgraded the certainty of evidence for study limitations.

Authors' conclusions: Early AST probably extends time to death of any cause and time to death from prostate cancer. It may slightly decrease the rate of skeletal events. Rates of serious adverse events and quality of life may be similar. It may increase fatigue and may increase the risk of heart failure. Better quality trials would be particularly important to better understand the outcomes related to possible treatment-related harm, for which we only found low-certainty evidence.

PubMed Disclaimer

Conflict of interest statement

The present work was supported by a grant from the German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung, BMBF, Förderkennzeichen 01KG1706).

Figures

1
1
Study flow diagram.
2
2
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
3
3
Forest plot of comparison: 1 Early vs deferred AST, outcome: 1.1 Time to death of any cause.
4
4
Funnel plot of comparison: 1 Early vs deferred AST, outcome: 1.1 Time to death of any cause.
5
5
Forest plot of comparison: 1 Early vs deferred AST, outcome: 1.3 Time to death from prostate cancer.
6
6
Forest plot of comparison: 1 Early vs deferred AST, outcome: 1.4 Adverse events.
1.1
1.1. Analysis
Comparison 1 Early vs deferred AST, Outcome 1 Time to death of any cause.
1.2
1.2. Analysis
Comparison 1 Early vs deferred AST, Outcome 2 Serious adverse events.
1.3
1.3. Analysis
Comparison 1 Early vs deferred AST, Outcome 3 Time to death from prostate cancer.
1.4
1.4. Analysis
Comparison 1 Early vs deferred AST, Outcome 4 Adverse events.
1.5
1.5. Analysis
Comparison 1 Early vs deferred AST, Outcome 5 Global quality of life.
1.6
1.6. Analysis
Comparison 1 Early vs deferred AST, Outcome 6 Time to disease progression.
2.1
2.1. Analysis
Comparison 2 Early vs deferred AST (subgroup analyses based on disease stage), Outcome 1 Time to death of any cause.
2.2
2.2. Analysis
Comparison 2 Early vs deferred AST (subgroup analyses based on disease stage), Outcome 2 Serious adverse events based on disease stage.
See this image and copyright information in PMC

Update of

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

EORTC 30846 {published data only}
    1. Kurth K, Schröder F, Fossa S, Hoekstra W, Karthaus P, Prijk L, et al. Early versus delayed endocrine treatment of T2‐T3 pN1‐3 M0 prostate cancer without local treatment of the primary tumour: final results of European organisation for the Research and Treatment of Cancer protocol 30846 after 13 years of follow‐up. Urology 2009;74:S34‐S35. - PubMed
    1. Schröder FH, Kurth K‐H, Fossa SD, Hoekstra W, Karthaus PP, Prijck L, et al. Early versus delayed endocrine treatment of T2‐T3 pN1‐3 M0 prostate cancer without local treatment of the primary tumour: Final results of European organisation for the research and treatment of cancer protocol 30846 after 13 years of follow‐up (a randomised controlled trial). European Urology 2009;55(1):14‐22. - PubMed
    1. Schröder FH, Kurth KH, Fossa SD, Hoekstra W, Karthaus PPM, Debois M, at al. Early versus delayed endocrine treatment of pN1‐3 M0 prostate cancer without local treatment of the primary tumor: Results of European Organisation for the Research and Treatment of Cancer 30846 ‐ A phase III study. Journal of Urology 2004;172(3):923‐7. - PubMed
EORTC 30891 {published data only}
    1. Studer U, Whelan P, Albrecht W, Wimpissinger F, Casselman J, Reijke TM, et al. Long term results of immediate versus deferred androgen deprivation in patients with no local treatment for T0‐4 N0‐2 M0 prostate cancer (EORTC 30891). Journal of Urology 2011;185:e144.
    1. Studer UE, Collette L, Whelan P, Albrecht W, Casselman J, Reijke T, et al. Which subgroups of patients with newly diagnosed T0‐4 N0‐2 mo prostate cancer not suitable for local treatment with curative intent (EORTC 30891) are at risk to die from prostate cancer and benefit from immediate androgen deprivation?. European Urology Supplements 2007;6(2):27.
    1. Studer UE, Collette L, Whelan P, Albrecht W, Casselman J, Reijke T, et al. Which subgroups of patients are at risk to die from prostate cancer and benefit from immediate androgen deprivation if they are not suitable for local treatment with curative intent of newly diagnosed prostate cancer T0‐4 N0‐2 M0 (EORTC 30891)?. Journal of Urology 2007;177:127.
    1. Studer UE, Hauri D, Dietrich D. Immediate vs deferred hormonal therapy for prostate cancer patients not suitable for curative local treatment. Journal of Urology 2002;167:303.
    1. Studer UE, Whelan P, Albrecht W, Casselman J, Reijke T, Hanri D, et al. Patients with asymptomatic prostate cancer T.0‐4 N.0‐2 M.0 not suitable for local definitive treatment: Do they need immediate androgen deprivation?. European Urology Supplements. 2005; Vol. 4:78.
EPCP {published data only}
    1. Brawer MK. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the Early Prostate Cancer Program. BJU International 2003;91(6):465‐6. - PubMed
    1. Iversen P. Bicalutamide 150 mg in addition to standard care in patients with early, non‐metastatic prostate cancer: Results from the SPCG‐6 study at a median follow‐up of 5.3 years. Journal of Urology 2004;171:311‐2. - PubMed
    1. Iversen P, Johansson J‐E, Lodding P, Kylmala T, Lundmo P, Klarskov P, et al. Bicalutamide 150 mg in addition to standard care for patients with early non‐metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group‐6 Study after a median follow‐up period of 7.1 years. Scandinavian Journal of Urology and Nephrology 2006;40(6):441‐52. - PubMed
    1. Iversen P, Johansson J‐E, Lodding P, Lukkarinen O, Lundmo P, Klarskov P, et al. Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3‐year median follow up from the Scandinavian Prostate Cancer Group Study Number 6. Journal of Urology 2004;172(5 Pt 1):1871‐6. - PubMed
    1. Iversen P, McLeod DG, See WA, Morris T, Armstrong J, Wirth MP, et al. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow‐up of 9.7 years. BJU International 2010;105(8):1074‐81. - PubMed
EST 3886 {published data only}
    1. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford D, Kiernan M, et al. Immediate hormonal therapy versus observation after radical prostatectomy and pelvic lymphadenectomy for node positive prostate cancer: At 10 years results of EST3886. Journal of Clinical Oncology 2004;22:399S‐S.
    1. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node‐positive prostate cancer. New England Journal of Medicine 1999;341(24):1781‐8. - PubMed
    1. Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, et al. Immediate versus deferred androgen deprivation treatment in patients with node‐positive cancer after radical prostatectomy and pelvic lympadenectomy. Lancet Oncology 2006;7(6):472‐9. - PubMed
    1. Messing EM, Monola J, Yao J, Kiernan M, Crawford ED, Wilding G, et al. Immediate vs delayed hormonal therapy (HT) in patients with nodal positive (N+) prostate cancer who had undergone radical prostatectomy (RP) plus pelvic lymphadenectomy (LND): Results of central pathology review (CPR). Journal of Urology 2004;171:383.
Granfors 2006 {published data only}
    1. Granfors T, Modig H, Damber JE, Tomic R. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: A prospective randomized study. Journal of Urology 1998;159(6):2030‐4. - PubMed
    1. Granfors T, Modig H, Damber JE, Tomic R. Long‐Term Followup of a Randomized Study of Locally Advanced Prostate Cancer Treated With Combined Orchiectomy and External Radiotherapy Versus Radiotherapy Alone. Journal of Urology 2006;176(2):544‐7. - PubMed
MRC {published data only}
    1. The Medical Reasearch Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council trial. British Journal of Urology 1997;79(2):235‐46. - PubMed
RTOG 85‐31 {published data only}
    1. Lawton CA, Winter K, Byhardt R, Sause WT, Hanks GE, Russell AH, et al. Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85‐31). International Journal of Radiation Oncology, Biology, Physics 1997;38(5):931‐9. - PubMed
    1. Lawton CA, Winter K, Grignon D, Pilepich MV. Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node‐positive adenocarcinoma of the prostate: Updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85‐31. Journal of Clinical Oncology 2005;23(4):800‐7. - PubMed
    1. Lawton CA, Winter K, Murray K, Machtay M, Mesic JB, Hanks GE, et al. Updated results of the phase III radiation therapy oncology group (RTOG) trial 85‐31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavourable prognosis carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics 2001;49(4):937‐46. - PubMed
    1. Pilepich MV, Winter K, Lawton C, Krisch RE, Wolkov H, Movsas B, et al. Androgen suppression adjuvant to radiotherapy in carcinoma of the prostate. Long‐term results of Phase III RTOG Study 85‐31. International Journal of Radiation Oncology, Biology, Physics 2003;57(2 Suppl):172‐3. - PubMed
SAKK 08/88 {published data only}
    1. Studer UE, Hauri D, Hanselmann S, Chollet D, Leisinger H‐J, Gasser T, et al. Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88. Journal of Clinical Oncology 2004;22(20):4109‐10. - PubMed
TROG 03.06/VCOG PR 0103 {published data only}
    1. Duchesne GM, Bassett J, D'Este C, Frydenberg M, Ledwich L, Millar JL, et al. TROG 03.06 and VCOG PR 0103: The “timing of androgen deprivation therapy in prostate cancer patients with a rising PSA (TOAD)” collaborative randomised phase III trial. Journal of Clinical Oncology 2015;33(15_suppl):5007. - PubMed
    1. Duchesne GM, Woo HH. The 'Timing of Androgen‐Deprivation therapy in incurable prostate cancer' protocol (TOAD)‐‐where are we now? Synopsis of the Victorian Cooperative Oncology Group PR 01‐03 and Trans‐Tasman Radiation Oncology Group 03.06 clinical trial. BJU International 2014;114(Suppl 1):9‐12. - PubMed
    1. Duchesne GM, Woo HH, Bassett JK, Bowe SJ, D'Este C, Frydenberg M, et al. Timing of androgen‐deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01‐03 [TOAD]): a randomised, multicentre, non‐blinded, phase 3 trial. Lancet Oncology 2016;17(6):727‐37. - PubMed
    1. Duchesne GM, Woo HH, King M, Bowe SJ, Stockler MR, Ames A, et al. Health‐related quality of life for immediate versus delayed androgen‐deprivation therapy in patients with asymptomatic, non‐curable prostate cancer (TROG 03.06 and VCOG PR 01‐03 [TOAD]): a randomised, multicentre, non‐blinded, phase 3 trial. Lancet Oncology 2017;18(9):1192‐201. - PubMed
VACURG {published data only}
    1. Blackard CE, Byar DP, Jordan WP, and the Veterans Administration Cooperative Urological Research Group. Orchiectomy for advanced prostatic carcinoma: a reevaluation. Urology 1973;1(6):553‐60. - PubMed
    1. Byar DP. VACURG studies of conservative treatment. Scandinavian Journal of Urology and Nephrology 1980;55:99‐102. - PubMed
    1. Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI monographs: a publication of the National Cancer Institute 1988;7:165‐70. - PubMed
    1. Hurst KS, Byar DP, and the Veterans Administration Cooperative Urological Research Group. An analysis of the effects of changes from the assigned treatment in a clinical trial of treatment for prostatic cancer. Journal of Chronic Diseases 1973;26(5):311‐24. - PubMed
    1. Veterans Administration Cooperative Urological Research Group. Carcinoma of the prostate: a continuing cooperative study. Journal of Urology 1964;91:590‐4. - PubMed

References to studies excluded from this review

Ahmed 2002 {published data only}
    1. Ahmed S, Trump DL. The case for early androgen deprivation: the data should not be ignored. Urologic Oncology 2002;7(2):77‐80. - PubMed
Akaza 2003 {published data only}
    1. Akaza H. Early androgen suppression may reduce disease progression and improve long term survival compared with deferred androgen suppression in locally advanced prostate cancer. Cancer Treatment Reviews 2003;29(3):224‐5. [DOI: 10.1016/S0305-7372(03)00119-1] - DOI - PubMed
Allepuz Losa 1999 {published data only}
    1. Allepuz Losa C, Gil Martínez P, Gil Sanz MJ, Rioja Sanz LA. Early versus late hormonal treatment in advanced prostate cancer [Tratamiento hormonal precoz vs tardio en el cancer avanzado de prostata.]. Actas Urologicas Espanolas 1999;23(7):557‐64. - PubMed
Alyea 1945 {published data only}
    1. Alyea EP. Early or late orchiectomy for carcinoma of the prostate. Journal of Urology 1945;53:143‐53.
Anderson 1999 {published data only}
    1. Anderson JB. Early versus deferred hormone therapy. European Urology 1999;36 Suppl 2:9‐13. - PubMed
Anderson 2004 {published data only}
    1. Anderson J. Bicalutamide 150 mg: practical prescribing in patients with early prostate cancer. BJU international 2004;94:758‐9. - PubMed
Barnes 1981 {published data only}
    1. Barnes R, Hadley H, Bergman RT. Immediate versus delayed endocrine therapy for prostatic carcinoma. Western Journal of Medicine 1981;134:345‐6. - PMC - PubMed
Bennett 1999 {published data only}
    1. Bennett CL, Tosteson TD, Schmitt B, Weinberg PD, Ernstoff MS, Ross SD. Maximum androgen‐blockade with medical or surgical castration in advanced prostate cancer: A meta‐analysis of nine published randomized controlled trials and 4128 patients using flutamide. Prostate Cancer and Prostatic Diseases 1999;2(1):4‐8. - PubMed
Bennett 2008 {published data only}
    1. Bennett CL, Sartor O, McLeod DG, Halabi S. Effects of age, health‐related quality of life, and education level on management after biochemical failure with watchful waiting versus hormonal therapy in men with prostate cancer: Results from the compare registry. Journal of Urology 2008;179(4, Supplement):109. [DOI: 10.1016/S0022-5347(08)60317-1] - DOI
Bertaccini 2012 {published data only}
    1. Bertaccini A, Marchiori D. The efficacy of degarelix on LUTS (Lower urinary tract symptoms) relief in patients with prostate cancer. Urologia 2012;79(3):197‐9. [DOI: 10.5301/RU.2012.9687] - DOI - PubMed
Bertelli 1990 {published data only}
    1. Bertelli A. Introduction: recent progress in therapy of prostatic carcinoma and other hormone dependent pathology with the use of agonistic analogs of LHRH [Introduzione: recenti progressi nella terapia del carcinoma prostatico e di altre patologie ormonodipendenti con l'impiego di agonisti analoghi all'LHRH]. Drugs under Experimental and Clinical Research 1990;16 Suppl:1‐2. - PubMed
Bex 1998 {published data only}
    1. Bex A, Rübben H. When to begin with androgen deprivation? [Wann ist mit einer Androgendeprivation zu beginnen?]. Der Urologe. Ausg. A 1998;37(2):133‐4. - PubMed
Bhayani 1999 {published data only}
    1. Bhayani SB, Andriole GL. Hormonal manipulation for rising PSA after radical prostatectomy. Seminars in Urologic Oncology 1999;17(3):148‐53. - PubMed
Bishop 2003 {published data only}
    1. Bishop M. The role of anti‐androgen monotherapy in the treatment of prostate cancer. BJU International 2003;92(6):653‐4. - PubMed
Black 2007 {published data only}
    1. Black PC, Basen‐Engquist K, Wang X, Swartz RJ, Eddings T, Matin SF, et al. A randomized prospective trial evaluating testosterone, haemoglobin kinetics and quality of life, during and after 12 months of androgen deprivation after prostatectomy: Results from the Postoperative Adjuvant Androgen Deprivation trial. BJU International 2007;100(1):63‐9. [DOI: ] - PubMed
Blasko 1997 {published data only}
    1. Blasko JC, Lange PH. Prostate cancer‐‐the therapeutic challenge of locally advanced disease. New England Journal of Medicine 1997;337(5):340‐1. - PubMed
Blom 1992 {published data only}
    1. Blom JH, Schröder FH. On the management of metastatic prostate cancer with LH‐RH analogs. Recent Results in Cancer Research 1992;124:33‐41. - PubMed
Blood 2010 {published data only}
    1. Blood PA. Neo‐adjuvant androgen deprivation therapy does not increase the risk of cardiovascular death in men treated for prostate cancer with curative intent. International Journal of Radiation Oncology, Biology, Physics 2010;78(3):S150‐1.
Boccon‐Gibod 2003 {published data only}
    1. Boccon‐Gibod L, Bertaccini A, Bono AV, Dev Sarmah B, Höltl W, Mottet N, et al. Management of locally advanced prostate cancer: a European consensus. International Journal of Clinical Practice 2003;57(3):187‐94. - PubMed
Boccon‐Gibod 2005 {published data only}
    1. Boccon‐Gibod L. Optimising hormone therapy in advanced disease. European Urology Supplements 2005;4:21‐9. [DOI: 10.1016/j.eursup.2005.08.001] - DOI
Boccon‐Gibod 2010 {published data only}
    1. Boccon‐Gibod L, Richaud P, Coloby P, Coulange C, Culine S, Davin JL, et al. First line indications for hormonal therapy in prostate cancer. Progres en Urologie 2010;20(2):109‐15. [DOI: ] - PubMed
Boehmer 2008 {published data only}
    1. Boehmer D. Combined radiotherapy and hormonal therapy in the treatment of prostate cancer. Frontiers of Radiation Therapy and Oncology 2008;41:26‐31. [DOI: ] - PubMed
Bolla 1997 {published data only}
    1. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff R, Storme G, et al. Immediate hormonotherapy with an LHRH analogue improves local control and survival in patients with locally advanced prostate cancer treated by radiotherapy. A randomized phase III clinical trial of the EORTC. European Journal of Cancer 1997;33:115.
Bolla 1999a {published data only}
    1. Bolla M, Collette L, Gonzalez D, Warde P, Dubois JB, Mirimanoff R, et al. Long term results of immediate adjuvant hormonal therapy with goserelin in patients with locally advanced prostate cancer treated with radiotherapy ‐ A phase III EORTC study. European Journal of Cancer 1999;35:S82. [DOI: 10.1016/S0959-8049(99)80699-6] - DOI
Bolla 1999b {published data only}
    1. Bolla M, Collette L, Gonzalez D, Warde P, Dubois JB, Mirimanoff R, et al. Long term results of immediate adjuvant hormonal therapy with goserelin in patients with locally advanced prostate cancer treated with radiotherapy. A phase III EORTC study [abstract]. International Journal of Radiation Oncology Biology Physics 1999;45(3 Suppl):147.
Bolla 2002 {published data only}
    1. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, et al. Long‐term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 2002;360(9327):103‐8. - PubMed
Bolla 2010 {published data only}
    1. Bolla M, Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. External irradiation with or without long‐term androgen suppression for prostate cancer with high metastatic risk: 10‐year results of an EORTC randomised study. Lancet Oncology 2010;11(11):1066‐73. - PubMed
Bolla 2012 {published data only}
    1. Bolla M, Laramas M, Association of Radiotherapy and Oncology of the Mediterranean arEa (AROME). Combined hormone therapy and radiation therapy for locally advanced prostate cancer. Critical Review in Oncology and Hematology 2012;84(Suppl 1):30‐34. - PubMed
Bonard 1966 {published data only}
    1. Bonard EC. Hormone and adjuvant therapy in advanced cancers [Le traitement hormonal et adjuvant des cancers avances]. Praxis 1966;55:676‐9. - PubMed
Bott 2004 {published data only}
    1. Bott SRJ. Management of recurrent disease after radical prostatectomy. Prostate cancer and prostatic diseases 2004;7:211‐6. [DOI: 10.1038/sj.pcan.4500732] - DOI - PubMed
Bourke 2013 {published data only}
    1. Bourke L, Kirkbride P, Hooper R, Rosario AJ, Chico TJ, Rosario DJ. Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost‐effectiveness?. British Journal of Cancer 2013;108(1):9‐13. [DOI: 10.1038/bjc.2012.523] - DOI - PMC - PubMed
Boustead 2007 {published data only}
    1. Boustead G, Edwards SJ. Systematic review of early vs deferred hormonal treatment of locally advanced prostate cancer: a meta‐analysis of randomized controlled trials. BJU International 2007;99:1383‐9. - PubMed
Boyer 1996 {published data only}
    1. Boyer M. The management of prostate cancer. Australian Prescriber 1996;19(1):22‐4.
Brower 2008 {published data only}
    1. Brower V. Watchful waiting beats androgen deprivation therapy in early prostate cancer. Journal of the National Cancer Institute 2008;100:1494‐6. - PubMed
Bruce 2012 {published data only}
    1. Bruce JY, Lang JM, McNeel DG, Liu G. Current controversies in the management of biochemical failure in prostate cancer. Clinical Advances in Hematology & Oncology 2012;10(11):716‐22. - PubMed
Christensen 1990 {published data only}
    1. Christensen MM, Aagaard J, Madsen PO. Reasons for delay of endocrine treatment in cancer of the prostate (until symptomatic metastases occur). Progress in Clinical and Biological Research 1990;359:7‐14; discussion 15‐1424. - PubMed
Cookson 1994 {published data only}
    1. Cookson MS, Sarosdy MF. Hormonal‐therapy for metastatic prostate‐cancer ‐ issues of timing and total androgen ablation. Southern Medical Journal 1994;87(1):1‐6. - PubMed
D'Amico 2004 {published data only}
    1. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6‐month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer ‐ A randomized controlled trial. Journal of the American Medical Association 2004;292(7):821‐7. [DOI: 10.1001/jama.292.7.821] - DOI - PubMed
D'Amico 2008 {published data only}
    1. D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer ‐ A randomized trial. Journal of the American Medical Association 2008;299(3):289‐95. [DOI: 10.1001/jama.299.3.289] - DOI - PubMed
deKernion 1990 {published data only}
    1. deKernion JB, Neuwirth H, Stein A, Dorey F, Stenzl A, Hannah J, et al. Prognosis of patients with stage D1 prostate carcinoma following radical prostatectomy with and without early endocrine therapy. Journal of Urology 1990;144:700‐3. [DOI] - PubMed
Duchesne 2006 {published data only}
    1. Duchesne GM, Syme R, Howell D. How early is early: androgen deprivation for prostate‐specific antigen relapse in prostate cancer. Journal of Clinical Oncology 2006;24(18):2964‐5. - PubMed
Garcia‐Albeniz 2015 {published data only}
    1. Garcia‐Albeniz X, Chan JM, Paciorek A, Logan RW, Kenfield SA, Cooperberg MR, et al. Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA‐only relapse. An observational follow‐up study. European Journal of Cancer 2015;51(7):817‐24. - PMC - PubMed
    1. Garcia‐Albeniz X, Chan JM, Paciorek AT, Logan RW, Kenfield SA, Cooperberg MR, et al. Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA‐only relapse. Journal of Clinical Oncology 2014;32(5S):Suppl, abstract 5003. - PMC - PubMed
Grossman 1986 {published data only}
    1. Grossman HB. Hormonal‐therapy of prostatic‐carcinoma ‐ is there a rationale for delayed treatment. Urology 1986;27:199‐204. - PubMed
Herr 1993 {published data only}
    1. Herr H, Kornblith AB, Ofman U. A comparison of the quality of life of patients with metastatic prostate cancer who received or did not receive hormonal therapy. Cancer 1993;71(3 Suppl):1143‐50. [DOI: 10.1002/1097-0142(19930201)71:3+%3C1143::AID-CNCR2820711437%3E3.0.CO; 2‐I] - DOI - PubMed
Hinkelbein 1998 {published data only}
    1. Hinkelbein W. Adjuvant or therapeutic androgen suppression in locoregional advanced prostatic carcinoma (RTOG 85‐31) [Adjuvante oder therapeutische Androgensuppression beim lokoregionar fortgeschrittenen Prostatakarzinom (RTOG 85‐31)]. Strahlentherapie und Onkologie 1998;174:385‐6. - PubMed
Horwitz 2008 {published data only}
    1. Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, et al. Ten‐year follow‐up of radiation therapy oncology group protocol 92‐02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. Journal of Clinical Oncology 2008;26(15):2497‐504. [DOI: ] - PubMed
Kim 2010 {published data only}
    1. Kim JO, Vaid M, Tyldesley S, Woods R, Pickles T. A population‐based study of cardiovascular (CV) mortality among patients with prostate cancer (PCa) treated with radical external beam radiation therapy (EBRT) with and without adjuvant androgen deprivation therapy (ADT) at a provincial cancer agency. Journal of Clinical Oncology 2010;28(15_suppl):4656. - PubMed
Konski 2005 {published data only}
    1. Konski A, Sherman E, Krahn M, Bremner K, Beck JR, Watkins‐Bruner D, et al. Economic analysis of a phase III clinical trial evaluating the addition of total androgen suppression to radiation versus radiation alone for locally advanced prostate cancer (Radiation Therapy Oncology Group protocol 86‐10). International Journal of Radiation Oncology, Biology, Physics 2005;63(3):788‐94. [DOI: ] - PubMed
Kozlowski 1991 {published data only}
    1. Kozlowski JM, Ellis WJ, Grayhack JT. Advanced prostatic carcinoma. Early versus late endocrine therapy. Urologic Clinics of North America 1991;18(1):15‐24. - PubMed
Lawton 2008 {published data only}
    1. Lawton CA, Bae K, Pilepich M, Hanks G, Shipley W. Long‐term treatment sequelae after external beam irradiation with or without hormonal manipulation for adenocarcinoma of the prostate: analysis of radiation therapy oncology group studies 85‐31, 86‐10, and 92‐02. International Journal of Radiation Oncology, Biology, Physics 2008;70(2):437‐41. [DOI: 10.1016/j.ijrobp.2007.06.050] - DOI - PMC - PubMed
Makarov 2006 {published data only}
    1. Makarov DV, Trock BJ, Humphreys EB, Mangold LA, Carducci MA, Partin AW, et al. Factors influencing prostate cancer specific mortality in patients receiving delayed androgen deprivation therapy for metastasis after biochemical recurrence following radical prostatectomy. Journal of Clinical Oncology 2006;24:abstract 4571.
Mickisch 2001 {published data only}
    1. Mickisch GH. Early versus deferred hormonal treatment for asymptomatic prostate cancer. Onkologie 2001;24:214‐220. - PubMed
Newling 2001 {published data only}
    1. Newling D. Advanced prostate cancer: Immediate or deferred hormone therapy?. European Urology 2001;39:15‐21. [DOI: 10.1159/000052545] - DOI - PubMed
Newling 2003 {published data only}
    1. Newling DW. Immediate or deferred hormonal therapy?. Scandinavian Journal of Urology and Nephrology 2003;37:16‐9. [DOI: 10.1080/03008880310006896] - DOI - PubMed
Pilepich 1995 {published data only}
    1. Pilepich MV, Krall JM, al‐Sarraf M, John MJ, Doggett RL, Sause WT, et al. Androgen deprivation with radiation‐therapy compared with radiation‐therapy alone for locally advanced prostatic‐aarcinoma ‐ a randomized comparative trial of the radiation‐therapy oncology group. Urology 1995;45:616‐23. [DOI: 10.1016/S0090-4295(99)80053-3] - DOI - PubMed
Pilepich 2001 {published data only}
    1. Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, et al. Phase III radiation therapy oncology group (RTOG) trial 86‐10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. International Journal of Radiation Oncology Biology Physics 2001;50(5):1243‐52. [DOI: ] - PubMed
Prezioso 2014 {published data only}
    1. Prezioso D, Iacono F, Romeo G, Ruffo A, Russo N, Illiano E. Early versus delayed hormonal treatment in locally advanced or asymptomatic metastatic prostatic cancer patient dilemma. World Journal of Urology 2014;32(3):661‐7. [DOI: 10.1007/s00345-013-1144-x] - DOI - PubMed
Richie 1997 {published data only}
    1. Richie JP. Stage D1 prostate cancer ‐ delayed androgen deprivation. Urology 1997;50:838‐9. [DOI: 10.1016/S0090-4295(97)00544-X] - DOI - PubMed
Schellhammer 2006 {published data only}
    1. Schellhammer PF. Timing of androgen deprivation therapy: Some questions answered, others not. Journal of the National Cancer Institute 2006;98(12):802‐3. - PubMed
Scher 1997 {published data only}
    1. Scher HI, Liebertz C, Kelly WK, Mazumdar M, Brett C, Schwartz L, et al. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. Journal of Clinical Oncology 1997;15(8):2928‐38. - PubMed
Schröder 1989 {published data only}
    1. Schröder FH. Early versus delayed endocrine treatment in metastatic prostatic cancer. Therapeutic Progress in Urological Cancers 1989;303:253‐60. - PubMed
Schröder 2004 {published data only}
    1. Schröder FH, Whelan P, Reijke TM, Kurth KH, Pavone‐Macaluso M, Mattelaer J, et al. Metastatic prostate cancer treated by flutamide versus cyproterone acetate ‐ Final analysis of the "European organization for research and treatment of cancer" (EORTC) protocol 30892. European Urology 2004;45:457‐64. [DOI: 10.1016/j.eururo.203.11.016] - DOI - PubMed
Shipley 2001 {published data only}
    1. Shipley W, Heydon K, Pilepich M. A secondary analysis of RTOG 86‐10: does the extent of progression at the time of initiating salvage hormone therapy influence survival in patients with prostate cancer who failed initial treatment with irradiation? [abstract]. Journal of Clinical Oncology 2001;20 (Pt 1):182a, Abstract 726.
Sieber 2004 {published data only}
    1. Sieber PR, Keiller DL, Kahnoski RJ, Gallo J, McFadden S. Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. Journal of Urology 2004;171(6 I):2272‐6. [DOI: ] - PubMed
Tyrrell 1998 {published data only}
    1. Tyrrell CJ, Kaisary AV, Iversen P, Anderson JB, Baert L, Tammela T, et al. A randomised comparison of 'Casodex' (R) (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology 1998;33(5):447‐56. - PubMed
van Aubel 1985 {published data only}
    1. Aubel OG, Hoekstra WJ, Schröder FH. Early orchiectomy for patients with stage D1 prostatic carcinoma. Journal of Urology 1985;134(2):292‐4. - PubMed
Van Cangh 2000 {published data only}
    1. Cangh PJ, Gala JL, Tombal B. Immediate vs. delayed androgen deprivation for prostate cancer. Prostate Supplement 2000;10:19‐25. - PubMed
Wirth 2003a {published data only}
    1. Wirth MP, Weissbach L, Marx FJ, Heckl W, Jellinghaus W, Riedmiller H, et al. Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node‐negative prostate cancer. European Urology 2004;45(3):267‐70. - PubMed
Wirth 2003b {published data only}
    1. With M, Froehner M.A. A review of studies of hormonal adjuvant therapy in prostate cancer. European Urology 1999;36(Suppl. 2):14‐9. - PubMed
Wirth 2003c {published data only}
    1. Wirth MP, Weissbach L, Marx FJ, Heckl W, Jellinghaus W, Riedmiller H, et al. Prospective randomised trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for stage pT3pN0 prostate cancer. Journal of Urology 2003;169:343. - PubMed
    1. With M, Froehner MA. A review of studies of hormonal adjuvant therapy in prostate cancer. European Urology 1999;36(Suppl. 2):14‐19. - PubMed
Zagars 1988 {published data only}
    1. Zagars GK, Johnson DE, Eschenbach AC, Hussey DH. Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: Long‐term results of a prospective randomized study. International Journal of Radiation Oncology, Biology, Physics 1988;14(6):1085‐91. - PubMed
Zierhut 1998 {published data only}
    1. Zierhut D. Therapy of nodal positive prostatic carcinoma: when should hormone therapy be started? [Therapie des nodal positiven Prostatakarzinomas: Wann sollte mit der Hormontherapie begonnen werden?]. Strahlentherapie und Onkologie 1998;174(7):382‐3. - PubMed
Zlotta 2006 {published data only}
    1. Zlotta AR, Schulman C. Immediate versus deferred androgen‐deprivation therapy for prostate cancer: the jury is still out. Nature Clinical Practice. Urology 2006;3(9):474‐5. [DOI: 10.1038/ncpuro0579] - DOI - PubMed
Zubek 2009 {published data only}
    1. Zubek VB, Konski A. Cost Effectiveness of Risk‐Prediction Tools in Selecting Patients for Immediate Post‐Prostatectomy Treatment. Molecular Diagnosis & Therapy 2009;13(1):31‐47. - PubMed

Additional references

Adolfsson 1999
    1. Adolfsson J. The natural history of early prostate cancer and the impact of endocrine treatment. European Urology 1999;36(Suppl 2):3‐8. - PubMed
Cocks 2012
    1. Cocks K, King MT, Velikova G, Castro Jr. G, Martyn St‐James M, Fayers PM, et al. Evidence‐based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. European Journal of Cancer 2012;48(11):1713–21. - PubMed
EAU 2017
    1. Mottet N, Bellmunt J, Briers E, Bolla M, Bourke L, Cornford P, et al. ESTRO – ESUR – SIOG Prostate Cancer Guidelines Panel. EAU – ESTRO – ESUR – SIOG Guidelines on Prostate Cancer. uroweb.org/guideline/prostate‐cancer (accessed 26 June 2017).
Endnote [Computer program]
    1. Thomson Reuters; www.endnote.com. Endnote. Version X5 or X6 or X7. Thomson Reuters; www.endnote.com, 1988‐2016.
Gibbs 1996
    1. Gibbs SJ, Plowman PN. Androgen deprivation and antagonism in the treatment of advanced prostatic carcinoma. Clinical Oncology 1996;8(6):346‐52. - PubMed
GLOBOCAN 2012
    1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. (editors). GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. globocan.iarc.fr (accessed 26 June 2017).
GRADEproGDT [Computer program]
    1. McMaster University (developed by Evidence Prime). GRADEproGDT. Version accessed prior to 19 March 2019. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015.
Guyatt 2008
    1. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck‐Ytter Y, Schünemann HJ. GRADE: what is "quality of evidence" and why is it important to clinicians?. BMJ (Clinical Research Ed.) 2008;336(7651):995‐8. [DOI: 10.1136/bmj.39490.551019.BE] - DOI - PMC - PubMed
Guyatt 2011
    1. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J. GRADE guidelines: 1. Introduction‐GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383‐94. [DOI: 10.1016/j.jclinepi.2010.04.026] - DOI - PubMed
Higgins 2002
    1. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine 2002;21(11):1539‐58. - PubMed
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. British Medical Journal 2003;327(7414):557‐560. - PMC - PubMed
Higgins 2011a
    1. Higgins JP, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration. Available from handbook.cochrane.org.
Higgins 2011b
    1. Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from handbook.cochrane.org.
Higgins 2011c
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Huggins 2002
    1. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. Journal of Urology 2002;167(2 Pt 2):948‐51. - PubMed
Kunath 2012
    1. Kunath F. LHRH antagonists versus standard androgen suppression therapy for advanced prostate cancer: a systematic review with comparative safety data analysis. www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42012002751 (accessed 5 April 2015). - PMC - PubMed
Kunath 2013
    1. Kunath F, Keck B, Rücker G, Motschall E, Wullich B, Antes G, Meerpohl JJ. Early versus deferred androgen suppression therapy for patients with lymph node‐positive prostate cancer after local therapy with curative intent: a systematic review. BMC Cancer 2013;13:131. - PMC - PubMed
Kunath 2014
    1. Kunath F, Grobe HR, Rücker G, Motschall E, Antes G, Dahm P, et al. Non‐steroidal antiandrogen monotherapy compared with luteinising hormone–releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer. Cochrane Database of Systematic Reviews 2014, Issue 6. [DOI: 10.1002/14651858.CD009266.pub2] - DOI - PMC - PubMed
Liberati 2009
    1. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine 2009;6(7):e1000100. [DOI: 10.1371/journal.pmed.1000100] - DOI - PMC - PubMed
Review Manager 2014 [Computer program]
    1. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Schünemann 2011
    1. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Tierney 2006
    1. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials 2007;8:16. [DOI: 10.1186/1745-6215-8-16] - DOI - PMC - PubMed

References to other published versions of this review

Nair 2002
    1. Nair B, Wilt T, MacDonald R, Rutks I. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database of Systematic Reviews 2002, Issue 1. [DOI: 10.1002/14651858.CD003506] - DOI - PubMed
Wilt 2001
    1. Wilt TJ, Nair B, MacDonald R, Rutks I. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database of Systematic Reviews 2001, Issue 4. [DOI: 10.1002/14651858.CD003506] - DOI - PubMed

Publication types

Substances